Draft Patents (Amendment), Rules, 2023
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
Has Malvinder Singh truly freed Ranbaxy from risk by opting for an out-of-court settlement with Pfizer over Lipitor as he has claimed? The markets and analysts certainly thought otherwise. Investors dumped the Ranbaxy stock last week after the company announced that it had closed the feud with Pfizer over cholesterol pill Lipitor. Ranbaxy agreed not to litigate any further against Pfizer's patents on the drug. Pfizer, in return, allowed it to launch generic Lipitor in the US by the end of 2011.
In a decision that will go a long way in soothing people living with HIV/AIDS (PLHAs), the Indian patent office today turned down the claim of a drug company to patent nevirapine. The drug is critical to HIV/AIDS treatment strategy, and is a crucial part of treatment for children affected by the virus. Patenting the drug would have meant limited access to HIV/AIDS treatment.
Subject to the approval of the shareholders and the usual regulatory and statutory rubber stamps, India's largest pharmaceutical company, Ranbaxy Laboratories, is expected, by the end of March 2009 to become a subsidiary of Daiichi Sankyo, one of the leading pharmaceutical companies of Japan.
Joe C Mathew India has rejected German drug major Boehringer Ingelheim's application for a pediatric form of anti-AIDS drug nevirapine bowing to objections from the country's civil society group and also to help local companies continue selling the medicine. The rejected patent application covers the syrup form of nevirapine, which is particularly important for children with HIV who are unable to swallow tablets. The rejection will allow generic drug companies like Aurobindo and Cipla to continue marketing low-cost versions of the medicine in the domestic market. BITTER PILL
Public interest groups and health advocacy firms have raised doubts over the validity of several medicine patents that have been granted by Indian patent offices in recent times. The medicines include tuberculosis (TB) drug moxifloxacin, antipsychotic olanzapine and valgancicloivir, a medicine often needed for HIV / AIDS patients.
The capacity of countries to take advantage of the patent system bears a relationship with their stage of development. This paper explores the relationship between economic development and domestic and foreign patenting behaviour. The study uses a unique data set covering 55 countries and 24 years. It determines the association of domestic patenting with gross domestic product per capita and openness to trade, and the association of foreign patenting with these variables and with foreign direct investment as a proportion of gdp.
Even as two multinationals and an Indian pharma company fight over a generic drug to treat stomach acid, a third giant has been pulled into legal battle. Pharma biggie Wyeth had filed a patent suit against Teva Pharmaceuticals and Mumbai-based Sun Pharma for its generic drug, Protonix. Wyeth is now also suing fellow biggie Novartis, whose generic unit Sandoz has applied to bring an injectable version of Protonix to market.
The Intellectual Property Rights (IPRs) Policy for Kerala puts forth the concept of 'knowledge commons' and 'commons licence' for traditional knowledge. The policy says that all traditional knowledge, including traditional medicine, must belong to the domain of "knowledge commons" and not to public domain. The system should be introduced through legal arrangements. While community or family custodians will have rights to knowledge that belonged to them, the rest of the traditional knowledge will belong to Kerala State.
Public Money: Health groups fear the new bill will facilitate private property with public funds (Pic By Subhabrata Das)
The government on Thursday decided to empower the agriculture export promotion agency(AEPA) to protect India's farm and horticulture products like Basmati rice from anyone patenting them anywhere in the world.